{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T05:38:21Z","timestamp":1784266701656,"version":"3.55.0"},"reference-count":46,"publisher":"Bentham Science Publishers Ltd.","issue":"46","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPD"],"published-print":{"date-parts":[[2019,4,26]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Aldosterone, through its actions on Mineralcorticosteroid Receptors (MR), controls fluid and electrolyte balance, but also exerts various direct deleterious actions on the vasculature. A number of aldosterone antagonists have been manufactured to reverse these effects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective:<\/jats:title><jats:p>A comprehensive review of the underlying mechanisms of the actions of aldosterone and its antagonists in cardiovascular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Method:<\/jats:title><jats:p>The relevant studies indexed in PubMed, Scopus and Google Scholar databases, published from 2003 to May 2018 were identified and reported.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Aldosterone binds to MR, activating them as intracellular transcription factors. Moreover, aldosterone, through its actions on MR, as well as on another not fully explored class of receptors, triggers several signaling pathways that produce rapid, non-genomic actions. In the vasculature, all these changes favor the establishment of inflammation and cardiovascular dysfunction, which, in turn, lead to or exacerbate various cardiovascular diseases. Mineralcorticosteroid Antagonists (MRA) are compounds that antagonize the action of aldosterone on MR. Spironolactone was the first steroidal MRA to be commercially used. It showed beneficial clinical results, but also a number of adverse effects. The next generation of steroidal MRA, exhibited lower potency but did not induce many of these adverse reactions, due to their high selectivity for MR. The third generation of MRA compromises the newly introduced non-steroidal MRA, which have a completely different chemical structure, they induce different and more drastic changes to MR, they are much more specific and currently under clinical trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>New MRA, which block the aldosterone induced pathways in the vasculature, hold promising results for the treatment of cardiovascular disease.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1381612825666190215100502","type":"journal-article","created":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T11:55:53Z","timestamp":1550231753000},"page":"5491-5499","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["The Mechanisms of Actions of Aldosterone and its Antagonists in Cardiovascular Disease"],"prefix":"10.2174","volume":"24","author":[{"given":"Panteleimon","family":"Pantelidis","sequence":"first","affiliation":[{"name":"2nd Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michail","family":"Sideris","sequence":"additional","affiliation":[{"name":"Women Health Research Unit, Queen Mary University of London, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margus","family":"Viigimaa","sequence":"additional","affiliation":[{"name":"Centre of Cardiology, North Estonia Medical Centre, Tallinn, Estonia; Institute of Health Technologies, Tallinn University of Technology, Tallinn, Estonia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Avranas","sequence":"additional","affiliation":[{"name":"2nd Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pavlos","family":"Deligkaris","sequence":"additional","affiliation":[{"name":"2nd Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioanna","family":"Zografou","sequence":"additional","affiliation":[{"name":"2nd Propaedeutic Department of Internal Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dragan","family":"Lovic","sequence":"additional","affiliation":[{"name":"Clinic for Internal Disease Intermedica, Cardiology department, Hypertension Center, Nis, Serbia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"309","author":"Coghlan J","year":"2009","unstructured":"Coghlan J, Tait JF. , Aldosterone: History and introduction Textbook of nephro-endocrinology, , 2009"},{"key":"ref=2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s10741-005-2343-3","volume":"10","author":"Williams G.H.","year":"2005","unstructured":"Williams GH. Heart Fail Rev, Aldosterone biosynthesis, regulation, and classical mechanism of action., 2005, 10, 7-13,","journal-title":"Heart Fail Rev"},{"key":"ref=3","author":"Arai K.","year":"2000","unstructured":"Arai K, Chrousos GP. , Aldosterone Deficiency and Resistance. In:De Groot LJ, Chrousos G, Dungan K, et al., Eds. Endotext. South Dartmouth (MA): MDText.com, Inc, , 2000"},{"key":"ref=4","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/clc.22025","volume":"35","author":"Markowitz M.","year":"2012","unstructured":"Markowitz M, Messineo F, Coplan NL. Clin Cardiol, Aldosterone receptor antagonists in cardiovascular disease: A review of the recent literature and insight into potential future indications., 2012, 35, 605-609,","journal-title":"Clin Cardiol"},{"key":"ref=5","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fimmu.2015.00340","volume":"6","author":"Gajjala P.R.","year":"2015","unstructured":"Gajjala PR, Sanati M, Jankowski J. Front Immunol, Cellular and molecular mechanisms of chronic kidney disease with diabetes mellitus and cardiovascular diseases as its comorbidities., 2015, 6, 340-,","journal-title":"Front Immunol"},{"key":"ref=6","first-page":"1","volume":"1","author":"H\u00e4ggstr\u00f6m M.","year":"2014","unstructured":"H\u00e4ggstr\u00f6m M, Richfield D. WikiJournal Med, Diagram of the pathways of human steroidogenesis., 2014, 1, 1-5,","journal-title":"WikiJournal Med"},{"key":"ref=7","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/cphy.c130037","volume":"4","author":"Bollag W.B.","year":"2014","unstructured":"Bollag WB. Compr Physiol, Regulation of aldosterone synthesis and secretion., 2014, 4, 1017-1055,","journal-title":"Compr Physiol"},{"key":"ref=8","author":"McKay L.","year":"2003","unstructured":"McKay L, Cidlowski J. Pharmacokinetics of Corticosteroids., , , 2003","journal-title":"Pharmacokinetics of Corticosteroids"},{"key":"ref=9","doi-asserted-by":"crossref","first-page":"T67","DOI":"10.1530\/JOE-17-0009","volume":"234","author":"DuPont J.J.","year":"2017","unstructured":"DuPont JJ, Jaffe IZ. J Endocrinol, 30 years of the mineralocorticoid receptor: The role of the mineralocorticoid receptor in the vasculature., 2017, 234, T67-T82,","journal-title":"J Endocrinol"},{"key":"ref=10","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1007\/s12020-018-1610-8","volume":"61","author":"Wu F.","year":"2018","unstructured":"Wu F, Lin Y, Liu Q. Endocrine, The emerging role of aldosterone\/mineralocorticoid receptors in the pathogenesis of erectile dysfunction., 2018, 61, 372-382,","journal-title":"Endocrine"},{"key":"ref=11","doi-asserted-by":"crossref","first-page":"R85","DOI":"10.1530\/EJE-13-0263","volume":"168","author":"Beuschlein F.","year":"2013","unstructured":"Beuschlein F. Eur J Endocrinol, Regulation of aldosterone secretion: from physiology to disease., 2013, 168, R85-R93,","journal-title":"Eur J Endocrinol"},{"key":"ref=12","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/MNH.0000000000000384","volume":"27","author":"Faulkner J.L.","year":"2018","unstructured":"Faulkner JL, Bruder-Nascimento T, Belin de Chantem\u00e8le EJ. Curr Opin Nephrol Hypertens, The regulation of aldosterone secretion by leptin: implications in obesity-related cardiovascular disease., 2018, 27, 63-69,","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"ref=13","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1515\/hmbci-2014-0013","volume":"19","author":"Even S.E.L.","year":"2014","unstructured":"Even SEL, Dulak-Lis MG, Touyz RM, Nguyen Dinh Cat A. Horm Mol Biol Clin Investig, Crosstalk between adipose tissue and blood vessels in cardiometabolic syndrome: implication of steroid hormone receptors (MR\/GR)., 2014, 19, 89-101,","journal-title":"Horm Mol Biol Clin Investig"},{"key":"ref=14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.semnephrol.2014.04.005","volume":"34","author":"Tamargo J.","year":"2014","unstructured":"Tamargo J, Solini A, Ruilope LM. Semin Nephrol, Comparison of agents that affect aldosterone action., 2014, 34, 285-306,","journal-title":"Semin Nephrol"},{"key":"ref=15","doi-asserted-by":"crossref","first-page":"353","DOI":"10.2147\/VHRM.S13779","volume":"7","author":"Nappi J.M.","year":"2011","unstructured":"Nappi JM, Sieg A. Vasc Health Risk Manag, Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure., 2011, 7, 353-363,","journal-title":"Vasc Health Risk Manag"},{"key":"ref=16","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1146\/annurev-physiol-012110-142222","volume":"73","author":"Thomas W.","year":"2011","unstructured":"Thomas W, Harvey BJ. Annu Rev Physiol, Mechanisms underlying rapid aldosterone effects in the kidney., 2011, 73, 335-357,","journal-title":"Annu Rev Physiol"},{"key":"ref=17","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s11906-014-0427-y","volume":"16","author":"Koenig J.B.","year":"2014","unstructured":"Koenig JB, Jaffe IZ. Curr Hypertens Rep, Direct role for smooth muscle cell mineralocorticoid receptors in vascular remodeling: novel mechanisms and clinical implications., 2014, 16, 427-,","journal-title":"Curr Hypertens Rep"},{"key":"ref=18","doi-asserted-by":"crossref","first-page":"132","DOI":"10.2174\/157436212800376708","volume":"7","author":"Verhovez A.A.","year":"2012","unstructured":"Verhovez AA, Williams T, Monticone S. Curr Signal Transduct Ther, Genomic and Non-genomic Effects of Aldosterone., 2012, 7, 132-141,","journal-title":"Curr Signal Transduct Ther"},{"key":"ref=19","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1093\/ndt\/gfg265","volume":"18","author":"Boldyreff B.","year":"2003","unstructured":"Boldyreff B, Wehling M. Nephrol Dial Transplant, Non-genomic actions of aldosterone: mechanisms and consequences in kidney cells., 2003, 18, 1693-1695,","journal-title":"Nephrol Dial Transplant"},{"key":"ref=20","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.mce.2011.07.020","volume":"350","author":"Odermatt A.","year":"2012","unstructured":"Odermatt A, Kratschmar DV. Mol Cell Endocrinol, Tissue-specific modulation of mineralocorticoid receptor function by 11\u03b2-hydroxysteroid dehydrogenases: An overview., 2012, 350, 168-186,","journal-title":"Mol Cell Endocrinol"},{"key":"ref=21","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.3390\/ijms18051032","volume":"18","author":"Funder J.W.","year":"2017","unstructured":"Funder JW. Int J Mol Sci, Aldosterone and mineralocorticoid receptors-physiology and pathophysiology., 2017, 18, 1032-,","journal-title":"Int J Mol Sci"},{"key":"ref=22","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1055\/s-0035-1564166","volume":"47","author":"Korah H.E.","year":"2015","unstructured":"Korah HE, Scholl UI. Horm Metab Res, An update on familial hyperaldosteronism., 2015, 47, 941-946,","journal-title":"Horm Metab Res"},{"key":"ref=23","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1111\/j.1365-2885.2009.01122.x","volume":"33","author":"Ovaert P.","year":"2010","unstructured":"Ovaert P, Elliott J, Bernay F, Guillot E, Bardon T. J Vet Pharmacol Ther, Aldosterone receptor antagonists--how cardiovascular actions may explain their beneficial effects in heart failure., 2010, 33, 109-117,","journal-title":"J Vet Pharmacol Ther"},{"key":"ref=24","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1159\/000368268","volume":"128","author":"Lang F.","year":"2014","unstructured":"Lang F, Ritz E, Alesutan I, Voelkl J. Nephron, Physiol, Impact of aldosterone on osteoinductive signaling and vascular calcification., 2014, 128, 40-45,","journal-title":"Nephron, Physiol"},{"key":"ref=25","first-page":"827","volume":"12","author":"Tamargo M.","year":"2017","unstructured":"Tamargo M, Tamargo J. Expert Opin Drug Discov, Future drug discovery in renin-angiotensin-aldosterone system intervention., 2017, 12, 827-848,","journal-title":"Expert Opin Drug Discov"},{"key":"ref=26","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/S0006-8993(02)03042-1","volume":"947","author":"Fischer A.K.","year":"2002","unstructured":"Fischer AK, von Rosenstiel P, Fuchs E, Goula D, Almeida OF, Cz\u00e9h B. Brain Res, The prototypic mineralocorticoid receptor agonist aldosterone influences neurogenesis in the dentate gyrus of the adrenalectomized rat., 2002, 947, 290-293,","journal-title":"Brain Res"},{"key":"ref=27","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/1744-9987.12679","volume":"22","author":"Fujii H.","year":"2018","unstructured":"Fujii H. Ther Apher Dial, Association between parathyroid hormone and cardiovascular disease., 2018, 22, 236-241,","journal-title":"Ther Apher Dial"},{"key":"ref=28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.steroids.2014.08.016","volume":"91","author":"Luther J.M.","year":"2014","unstructured":"Luther JM. Steroids, Effects of aldosterone on insulin sensitivity and secretion., 2014, 91, 54-60,","journal-title":"Steroids"},{"key":"ref=29","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/s11906-011-0182-2","volume":"13","author":"Briet M.","year":"2011","unstructured":"Briet M, Schiffrin EL. Curr Hypertens Rep, The role of aldosterone in the metabolic syndrome., 2011, 13, 163-172,","journal-title":"Curr Hypertens Rep"},{"key":"ref=30","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s11906-016-0649-2","volume":"18","author":"Haller H.","year":"2016","unstructured":"Haller H, Bertram A, Stahl K, Menne J. Curr Hypertens Rep, Finerenone: A New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: An Opportunity in Patients with CKD?, 2016, 18, 41-,","journal-title":"Curr Hypertens Rep"},{"key":"ref=31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s40292-018-0252-5","volume":"25","author":"Neves M.F.","year":"2018","unstructured":"Neves MF, Cunha AR, Cunha MR, Gismondi RA, Oigman W. High Blood Press Cardiovasc Prev, The role of renin-angiotensin-aldosterone system and its new components in arterial stiffness and vascular aging., 2018, 25, 137-145,","journal-title":"High Blood Press Cardiovasc Prev"},{"key":"ref=32","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.jsbmb.2017.01.016","volume":"176","author":"Wehling M.","year":"2018","unstructured":"Wehling M. J Steroid Biochem Mol Biol, Rapid actions of aldosterone revisited: Receptors in the limelight., 2018, 176, 94-98,","journal-title":"J Steroid Biochem Mol Biol"},{"key":"ref=33","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.freeradbiomed.2012.05.011","volume":"53","author":"Queisser N.","year":"2012","unstructured":"Queisser N, Schupp N. Free Radic Biol Med, Aldosterone, oxidative stress, and NF-\u03baB activation in hypertension-related cardiovascular and renal diseases., 2012, 53, 314-327,","journal-title":"Free Radic Biol Med"},{"key":"ref=34","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.2174\/1389450119666180326125926","volume":"19","author":"Kolodziejczyk P.","year":"2018","unstructured":"Kolodziejczyk P, Gromotowicz-Poplawska A, Aleksiejczuk M, Chabielska E, Tutka P, Miltyk W. Curr Drug Targets, New sides of aldosterone action in cardiovascular system as potential targets for therapeutic intervention., 2018, 19, 1968-1979,","journal-title":"Curr Drug Targets"},{"key":"ref=35","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1111\/j.1751-7176.2011.00511.x","volume":"13","author":"Epstein M.","year":"2011","unstructured":"Epstein M, Calhoun DA. J Clin Hypertens (Greenwich), Aldosterone blockers (mineralocorticoid receptor antagonism) and potassium-sparing diuretics., 2011, 13, 644-648,","journal-title":"J Clin Hypertens (Greenwich)"},{"key":"ref=36","doi-asserted-by":"crossref","first-page":"T125","DOI":"10.1530\/JOE-16-0600","volume":"234","author":"Kolkhof P.","year":"2017","unstructured":"Kolkhof P, B\u00e4rfacker L. J Endocrinol, 30 years of the mineralocorticoid receptor: Mineralocorticoid receptor antagonists: 60 years of research and development., 2017, 234, T125-T140,","journal-title":"J Endocrinol"},{"key":"ref=37","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.coph.2016.02.005","volume":"27","author":"Yang J.","year":"2016","unstructured":"Yang J, Young MJ. Curr Opin Pharmacol, Mineralocorticoid receptor antagonists-pharmacodynamics and pharmacokinetic differences., 2016, 27, 78-85,","journal-title":"Curr Opin Pharmacol"},{"key":"ref=38","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/164_2016_76","volume":"243","author":"Kolkhof P.","year":"2016","unstructured":"Kolkhof P, Jaisser F, Kim S-Y, Filippatos G, Nowack C, Pitt B. Heart Fail, Steroidal and novel non-steroidal mineralocorticoid receptor antagonists in heart failure and cardiorenal diseases: Comparison at Bench and Bedside., 2016, 243, 271-305,","journal-title":"Heart Fail"},{"key":"ref=39","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1007\/s40264-014-0196-1","volume":"37","author":"Ben Salem C.","year":"2014","unstructured":"Ben Salem C, Badreddine A, Fathallah N, Slim R, Hmouda H. Drug Saf, Drug-induced hyperkalemia., 2014, 37, 677-692,","journal-title":"Drug Saf"},{"key":"ref=40","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","volume":"37","author":"Filippatos G.","year":"2016","unstructured":"Filippatos G, Anker SD, B\u00f6hm M. Eur Heart J, A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease., 2016, 37, 2105-2114,","journal-title":"Eur Heart J"},{"key":"ref=41","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","volume":"314","author":"Bakris G.L.","year":"2015","unstructured":"Bakris GL, Agarwal R, Chan JC. JAMA, Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial., 2015, 314, 884-894,","journal-title":"JAMA"},{"key":"ref=42","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1253\/circj.CJ-16-0122","volume":"80","author":"Sato N.","year":"2016","unstructured":"Sato N, Ajioka M, Yamada T. Circ J, A randomized controlled study of finerenone vs. eplerenone in japanese patients with worsening chronic heart failure and diabetes and\/or chronic kidney disease., 2016, 80, 1113-1122,","journal-title":"Circ J"},{"key":"ref=43","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jdiacomp.2016.11.021","volume":"31","author":"Katayama S.","year":"2017","unstructured":"Katayama S, Yamada D, Nakayama M. J Diabetes Complications, A randomized controlled study of finerenone versus placebo in Japanese patients with type 2 diabetes mellitus and diabetic nephropathy., 2017, 31, 758-765,","journal-title":"J Diabetes Complications"},{"key":"ref=44","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1097\/HJH.0b013e328364c2a2","volume":"31","author":"Lovic D.","year":"2013","unstructured":"Lovic D, Stojanov V, Jakovljevi\u0107 B. J Hypertens, Prevalence of arterial hypertension in Serbia: PAHIS study., 2013, 31, 2151-2157,","journal-title":"J Hypertens"},{"key":"ref=45","doi-asserted-by":"crossref","first-page":"389","DOI":"10.5152\/akd.2014.5115","volume":"14","author":"Lovic D.","year":"2014","unstructured":"Lovic D, Erdine S, Catako\u011flu AB. Anadolu Kardiyol Derg, How to estimate left ventricular hypertrophy in hypertensive patients., 2014, 14, 389-395,","journal-title":"Anadolu Kardiyol Derg"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.2174\/1381612823666170206154706","volume":"23","author":"Faselis C.","year":"2017","unstructured":"Faselis C, Boutari C, Doumas M, Imprialos K, Stavropoulos K, Kokkinos P. Curr Pharm Des, Novel drugs for hypertension and heart failure: Struggling for a place under the sun., 2017, 23, 1540-1550,","journal-title":"Curr Pharm Des"}],"container-title":["Current Pharmaceutical Design"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/170006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,14]],"date-time":"2024-07-14T20:32:16Z","timestamp":1720989136000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/170006\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,26]]},"references-count":46,"journal-issue":{"issue":"46","published-print":{"date-parts":[[2019,4,26]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1381612825666190215100502","relation":{},"ISSN":["1381-6128"],"issn-type":[{"value":"1381-6128","type":"print"}],"subject":[],"published":{"date-parts":[[2019,4,26]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-15","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-02-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-26","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}